CTC NOTICE OF MODIFICATIONS
Version 2.0 Publish Date: April 30, 1999
Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)
Rectal bleeding/ hematochezia
Hemorrhage - Other (Specify site, ___________)
Alkaline phosphatase Bilirubin
Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.
GGT ( - Glutamyl transpeptidase)
Hepatic enlargement Note: Grade Hepatic... Hypoalbuminemia
Liver dysfunction/ failure (clinical)
The rows for Hepatic enlargement and its Note were shaded to indicate the relationship between VOD and BMT.
The Note for Hepatic enlargement was revised to Grade Hepatic enlargement only for treatment related adverse event including Veno-Occlusive Disease.
Portal vein flow
The Note for Liver dysfunction/failure (clinical) was deleted.
SGOT (AST) (serum glutamic oxaloacetic transaminase)
SGPT (ALT) (serum glutamic pyruvic transaminase)
Hepatic - Other (Specify, __________)
Cancer Therapy Evaluation Program Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS March 1998
Revised March 23, 1998